SOURCE: Ablynx

November 09, 2010 01:42 ET

Ablynx Eligible for Milestone Payment as Pfizer Initiates Phase I Clinical Trial With a Second ANTI-TNF-alpha Nanobody

GHENT, BELGIUM--(Marketwire - November 9, 2010) -


Ablynx [Euronext Brussels: ABLX] today announced that it is now eligible for a milestone payment of $3 million as a result of the initiation by Pfizer of a new Phase I clinical study in healthy volunteers for a second Nanobody (PF-05230905) targeting tumour necrosis factor alpha (TNF-alpha).

Pfizer's lead anti-TNF-alpha Nanobody, ATN-103, is currently in a Phase II study in patients with rheumatoid arthritis (RA). Pfizer has completed recruitment for the Phase II study.

Ablynx entered into an exclusive research collaboration and license agreement in November 2006 with Wyeth, which was acquired by Pfizer. As part of the agreement, Pfizer now owns the exclusive worldwide development and commercialisation rights to the anti-TNF-alpha Nanobody programme. This deal has a potential value to Ablynx of $212.5 million in up-fronts and milestone payments. Ablynx will now have earned a total of $10 million in milestone payments from Pfizer. In addition, Ablynx is eligible to receive royalties on product sales.

Dr Edwin Moses, CEO and Chairman of Ablynx commented: "Pfizer's decision to advance a second anti-TNF-alpha Nanobody into the clinic underscores the importance and potential of this programme. We are very pleased with the progress made in this TNF-alpha partnership, and we continue to work with Pfizer to discover additional anti-TNF-alpha Nanobodies which could have important therapeutic applications. Pfizer is well placed to maximize the value of these Nanobody programmes based on their proven success in the TNF-alpha field and their significant biologics expertise. We would anticipate the study to be completed by the second quarter of 2011. There are now five Nanobodies in clinical development."

About Ablynx [Euronext Brussels: ABLX] - http://www.ablynx.com

Founded in 2001 in Ghent, Belgium, Ablynx is a biopharmaceutical company focused on the discovery and development of Nanobodies, a novel class of therapeutic proteins based on single-domain antibody fragments, for a range of serious and life-threatening human diseases. The Company currently has over 240 employees. Ablynx completed a successful IPO on Euronext Brussels [ABLX] on 7 November 2007 and raised EUR50 million through an SPO in March 2010.



[HUG#1460256]



Complete version of the press release: http://hugin.info/137912/R/1460256/399500.pdf



This announcement is distributed by Thomson Reuters on behalf of

Thomson Reuters clients. The owner of this announcement warrants that:

(i) the releases contained herein are protected by copyright and

other applicable laws; and

(ii) they are solely responsible for the content, accuracy and

originality of the information contained therein.

Source: Ablynx via Thomson Reuters ONE

Contact Information

  • For more information, please contact Ablynx:

    Dr. Edwin Moses
    Chairman and CEO
    t: +32 (0)9 262 00 07
    m: +44 (0)7771 954 193 / +32 (0)473 39 50 68
    e: Email Contact

    Eva-Lotta Allan
    Chief Business Officer
    t: +32 (0)9 262 00 75
    m: +32 (0)475 78 36 21 / +44 (0)7990 570 900
    e: Email Contact